Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Videx (didanosine)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved June 1996

Specific Treatments:

HIV infection

General Information

A smaller dosage of Videx has been approved for the treatment of HIV infection in adults and children when antiretroviral therapy is warranted. The new Videx tablet is 35% smaller than the original tablet. In addition, the taste has been improved with a mandarin orange flavor. The new Videx tablets will be manufactured in 25 mg, 50 mg, 100 mg, and 150 mg tablets. The new tablet will be available immediately.

Clinical Results

Recent results from four large-scale clinical trials show that Vide; either alone or in combination, delays the onset of AIDS and improves survival.

Mechanism of Action

Videx belongs to a class of drugs known as nucleoside analogs. It works by inhibiting reverse transcriptase, an enzyme required for replication of HIV.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation